Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
FDA approved imlunestrant, marketed as Inluriyo by Eli Lilly, for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following progression after at least one line of endocrine therapy.
The approval reinforces the role of mutation testing in breast-cancer treatment decisions, particularly after endocrine resistance emerges.
For oncology systems, each biomarker-linked approval adds pressure to make molecular testing timely and routine.
Why It Matters
Breast-cancer treatment is becoming more molecularly segmented, with ESR1 mutation status guiding therapy after endocrine progression.
What to Watch
Watch testing patterns, sequencing with CDK4/6 inhibitors and uptake outside academic cancer centres.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDABreast CancerESR1Precision Oncology